Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Talks Up Monetization Of First To Files Like Lipitor, Diovan, Actos if FDA Issues Stay Foggy; Are Big Launches Imperilled?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - With no clarity emerging whatsoever on how Ranbaxy Laboratories Ltd. will resolve its five-year long dispute with U.S. FDA - which has led to a blanket ban on drugs manufactured at one of Ranbaxy's largest India-based sites - analysts now speculate that the company will most likely "explore monetizing" its key first-to-file opportunities in the U.S. like Lipitor (atorvastatin), Diovan (valsartan), Nexium (esomeprazole) and Actos (pioglitazone)

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts